SP100 家族在胰腺腺癌中的表达、预后价值及其机制。
Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma.
机构信息
State Key Lab of Molecular Oncology and Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
出版信息
Aging (Albany NY). 2023 Jun 22;15(12):5569-5591. doi: 10.18632/aging.204811.
BACKGROUND
Pancreatic adenocarcinoma (PAAD) is one of the most aggressive malignancies with a very poor prognosis. Exploring more therapeutic targets and prognostic biomarkers is of great significance to improve the prognosis of PAAD patients. Increasing evidence supports that the speckled protein (SP) 100 family is associated with human cancer and immune disorders. However, the function of the SP100 family members in PAAD is still unclear.
METHODS
R, Cytoscape, cBioPortal, and other software and online databases were used to comprehensively analyze the expression characteristics, prognostic value, and oncogenic mechanism of the SP100 family in PAAD.
RESULTS
The high expression of SP100 family members in PAAD was significantly correlated with poor clinicopathological features and poor prognosis of PAAD patients. Mechanistically, TP53 mutations were significantly associated with the expression levels of the SP100 family members, which were significantly coexpressed with M6A methylation regulators and were activated in multiple oncogenic pathways, including the EMT pathways. Moreover, we found that their expression levels were significantly correlated with the sensitivity of multiple traditional chemotherapeutic drugs.
CONCLUSION
The SP100 family is closely related to the occurrence and development of PAAD and can be used as a new biomarker and therapeutic target for patients with PAAD.
背景
胰腺导管腺癌（PAAD）是一种侵袭性很强、预后极差的恶性肿瘤。探索更多的治疗靶点和预后生物标志物对于改善 PAAD 患者的预后具有重要意义。越来越多的证据表明，斑点蛋白（SP）100 家族与人类癌症和免疫紊乱有关。然而，SP100 家族成员在 PAAD 中的功能尚不清楚。
方法
使用 R、Cytoscape、cBioPortal 和其他软件以及在线数据库，全面分析 SP100 家族在 PAAD 中的表达特征、预后价值和致癌机制。
结果
PAAD 中 SP100 家族成员的高表达与 PAAD 患者不良的临床病理特征和预后显著相关。在机制上，TP53 突变与 SP100 家族成员的表达水平显著相关，它们与 M6A 甲基化调节剂显著共表达，并在多种致癌途径中被激活，包括 EMT 途径。此外，我们发现它们的表达水平与多种传统化疗药物的敏感性显著相关。
结论
SP100 家族与 PAAD 的发生发展密切相关，可作为 PAAD 患者新的生物标志物和治疗靶点。
Zotero 插件